GENFIT is a biopharmaceutical company developing therapies for rare, life‑threatening liver diseases, with a focus on acute‑on‑chronic liver failure (ACLF) and its complications such as hepatic encephalopathy. Its pipeline includes reformulated nitazoxanide (NTZ) that received FDA orphan‑drug designation for ACLF, as well as assets for primary biliary cholangitis, cholangiocarcinoma, and metabolic liver disorders.
Funding
$508.6K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Patients with rare, life‑threatening liver diseases such as acute‑on‑chronic liver failure (ACLF), hepatic encephalopathy, cholangiocarcinoma, urea‑cycle disorders, and primary biliary cholangitis have limited therapeutic options and often lack effective treatments.
Solution
Genfit develops disease‑modifying therapies that target key pathophysiological pathways in these conditions. Its lead asset, G1090N (a reformulated nitazoxanide), is being advanced for ACLF and has received FDA orphan‑drug designation, indicating a focus on unmet medical need. The company also commercializes Iqirvo® (elafibranor) for primary biliary cholangitis following accelerated regulatory approvals. Genfit’s R&D pipeline spans eight programs across multiple stages, including therapeutic candidates for cholangiocarcinoma, urea‑cycle disorders, and organic acidemias, as well as diagnostic tools for NASH/MASH and ammonia monitoring. The organization leverages data‑science, regulatory expertise, and market‑access capabilities to accelerate development and bring these products to patients.
Target Audience
Genfit’s primary customers are pharmaceutical partners, healthcare providers, and patients seeking advanced treatments for rare, severe liver diseases and related metabolic disorders.
Features
- G1090N reformulation of nitazoxanide designed to unlock clinical potential in ACLF patients
- Iqirvo® (elafibranor) with accelerated FDA, EMA, and MHRA approvals for primary biliary cholangitis
- Eight‑program pipeline covering ACLF, hepatic encephalopathy, cholangiocarcinoma, urea‑cycle disorders, organic acidemias, and diagnostics for NASH/MASH and ammonia
- Integrated data‑science platform to inform target selection, biomarker development, and trial design
- Dedicated regulatory affairs and market‑access teams to navigate orphan‑drug pathways and reimbursement strategies